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The  ability of class  II  antigens  to  serve  as  restriction  elements  in  immune  cell 
interactions  has  been  demonstrated  in  a  variety  of  systems  (1,  2).  Among  these 
molecules, the I-A and I-E subregion-encoded determinants are the best studied (3); 
a substantial body of experimental evidence suggests that T  cell associative recognition 
of antigenic  determinants  and  I-A  (2)  or  I-E  (I)  -encoded  molecules  on  antigen- 
presenting ceils (APC)  is a  source of the genetic restrictions found in the generation 
of immunity. 
Genetic restrictions in antigen-specific immune suppression have also been described 
(4).  In  T  suppressor  (Ts)  cell-cell interactions,  both  Igh  (5)  and  I-J  (6)  -encoded 
determinants  have  been  shown  to  serve  as  restriction  elements.  The  mechanism 
responsible for  Igh  restriction appears  to  involve Vn-anti  VH  interactions  between 
different T  cell subsets (5). Although I-J has been detected on Ts cells in many systems 
(4,  6)  and  I-J restriction has  been  demonstrated  in  many of these systems  (6),  the 
cellular mechanism(s) responsible for this I-J restriction is unclear. 
Recently, we defined an  I-J-restricted event  in  the activation of Ts  effector ceils 
(Ts3) in the azobenzenearsonate (ABA) system (7). Here, we report that an I-J  +, I-A- 
APC may be responsible for this restriction. Furthermore, the fact that mice pretreated 
with low doses of cyclophosphamide are deficient in these cells may help explain how 
this drug acts to inhibit Ts function in vivo. 
Materials  and  Methods 
Mice.  A/J,  BALB/c,  and  (BALB/c  ×  A/J)F1  (CAF1)  mice  were  purchased  from  The 
Jackson Laboratory, Bar Harbor, ME. 
Antibody and Complement (C')  Treatment.  Monoclonal anti-I-J  k antibody (WF C.12.8)  from 
ascites  fluid was  the  generous  gift  of Dr.  Carl  Waltenbaugh,  Northwestern  University. A 
hybridoma line producing anti-I-A  k monoclonal antibody (10.2.16)  was obtained from the Salk 
Institute, San Diego, CA. Antibodies were purified on protein A columns and diluted appro- 
priately before use. Erythrocyte-free spleen ceils were suspended at a concentration of I07 cells/ 
ml of diluted antibody. After t5 rain on ice, cells were incubated for 15 min at 37°C in  10% 
CO2.  After washing, cells were suspended at a  concentration of 107 cells/ml of 1:15  diluted 
rabbit C' (Pel-Freez Biologicals, Rogers, AR) and incubated for 45 min at 37°C in  10% COs. 
The cells were subsequently washed extensively, coupled with the activated diazonium salt of 
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TABL~  I 
Antigen Presentation by I-J  + APC and TsF2 are.  Required to Activate Ts3 
Percent specific  release 
Treatment of APC*  TsF2~  ABA(CA)F,§  Uncoupled (CA)FI 
100:1  33:1  ll:l  100:1  33:1  11:1 
C'  -  60  46  4(I  0  fi  5 
C"  +  15  9  6  0  5  5 
Anti I-J  u + C'  -  51  43  41  3  5  2 
Anti I-J  k + C'  +  63  53  45  2  2  4 
Negative control  -  5  5  4  7  6  4 
* 3 ×  10  v APC from the spleen  of (CA)F~ mice were treated with rabbit C' alone or monoclonal 
anti I-J  k (a gift ofC. Wa[tenbaugh) plus C'. These cells  wece used to prime (CA)F~ recipients. 
:~ TsF~ was administered  on days 4 and 5 after priming  in a total dose  of 6 × i0  7  ceil equivalents. 
§ ABA-specific  cytotoxicity  was assayed  on Con A (CA)F~ blast cells  that were  coupled with ABA 
or left uncoupled  in a standard 4-h mCr release assay after restimulation of the primed T cells 
with ABA-coupled (CA)F~ cells. Targets were Con A-induced (CA)F~ blast cells that were 
coupled with ABA or left uncoupled 
arsanilic acid, and injected as described previously (8). 
Immunization of  Animals.  Mice were immunized subcutaneously with 1-3 ×  10 7 ABA-coupled 
spleen cells. This procedure has been described elsewhere (8). 
Cytotoxic T Lymphocyte (CTL) Assay and Delayed-type Hypersensitivity (DTH).  CTL and DTH 
assays have been described elsewhere (8, 9). Briefly, mice were challenged in the footpad with 
30 ~1  10 raM-active ABA solution 5 d  after immunization. 24 h  later, DTH was measured by 
an investigator unfamiliar with the experimental groups. 0-1  d  later, 7 ×  10  s  responders were 
cultured with 6  ×  106 ABA-coupled x-irradiated (1,500 rad) spleen cells in 2 ml for 5 d. CTL 
responses were then measured by 51Cr-release assay against ABA-coupled concanavalin A  (Con 
A) blast cells in standard 4-h assay. 
Induction and Administration of Second Order Suppressor Factor (TsFz).  Naive A/J mice received 
1.5 ×  108 cell equivalents over 5 d of conventional or monoclonal TsF1. TsF2 was prepared from 
spleen cell freeze-thaw lysates from these mice as described previously (7).  Mice receiving TsF2 
were injected with 3 X  10  7 cell equivalents/day on days 4 and 5. 
Cyclophosphamide Treatment.  Mice receiving cyclophosphamide (Cytotoxan; Mead Johnson 
& Co.,  Evansville, IN)  were injected intraperitoneally with 20  mg/kg  (as noted in text)  2  d 
before they were killed. Spleen cells were subsequently ABA coupled and injected subcutane- 
ously into two separate dorsal sites as described previously (8). 
Results  and  Discussion 
To generate ABA-specific Tsa effector cells, I-J-restricted presentation of hapten  is 
required  (7).  To  Characterize  the  cell  (or  cells)  responsible  for  this  restriction,  we 
treated ABA-coupled APC  with monoclonal anti-I-J antibody and  C' before immu- 
nization. This treatment removed APC  required for Ts3  but  not for CTL  induction 
(Table  I)  or  for DTH  priming  (data  not shown). It 'should be noted that  the same 
monoclonal antibody  has  been  used  to  lyse  an  I-J  +  APC  in  another  experimental 
system.  1 Because there  is  no  representation of ABA  in  the  immunized  animal  (see 
Table II, ref.  7), we were confident that these immunizing cells were the only source 
of ABA presentation for Ts3 induction in the recipient mice. 
To characterize the expression of I-A encoded determinants  on  the I-J  +  APC, we 
adopted a  slightly different protocol. Immunization  with monoclonal anti-I-A  k +  C'- 
treated ABA-coupled spleen cells fails to prime for anti-ABA DTH  or CTL  responses 
(Table  II  and  Table  III);  in  the  absence of a  positive  response it  is  impossible to 
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TAnLE  II 
The APC Required for Activating  Tsa May Be I-A Negative 
355 
[mmunization 
Percent specific release 
ABA-(GA)F~  Uncoupled  (CA)F~ 
A/J TsF2  Con A  blasts  Con A blasts 
100:1  33:1  lhl  100:1  33:1  11:1 
ABA/A/J 
ABA/BALB/c 
ABA-A/J +  ABA/BALB/c 
ABA/A/J  +  ABA/BALB/c 
ABA-A/J (anti-I-A  k +  C') 
+  ABA/BALB/c 
ABA-A/J (anti-l-A k +  12') 
+  ABA/BALB/c 
Negative control 
-  40.6  32.8  21.8  0.9  7,8  2.8 
+  52.8  38.0  24.9  7.6  11,4  3.9 
--  52.6  47.8  37.4  12.8  14.0  17.1 
+  14.2  9.2  8.7  4.3  2.7  4.5 
+  8.1  6.9  2.4  2.1  0.8  3.3 
46.2  31.7  19.4  1.6  3.0  7.2 
4.6  1.1  8.3  0.6  8,6  4.1 
(GA)Ft were immunized with either 2 ×  10  7 ABA-A/J subcutaneously  2 X  10 7 ABA/BALB/c subcutaneously,  or both (in 
separate  dorsal  sites).  In  some groups  A/J  cells  were  treated  with  monoclonal  anti-I-A  k  (10,2,16)  and  G' before  ABA 
coupling, A/J TsF2 was adminhtered  on days 4 and 5 after priming in a  total dose of 6  X  10  7 cell equivalents, 
TAaLE  III 
1-J  + APC is I-A- and x-Ray (1,500 rad) Resistant 
Immunization  A/J TsF2  DTH  P values 
A/J-ABA +  BALB-ABA 
A/J-ABA +  BALB-ABA 
(Anti-I-A  k +  G')-A/J-ABA +  BALB-ABA 
(Anti-I-A  k +  C')-A/J-ABA +  BALB-ABA 
(Anti-I A ~ +  G')-A/J ABA 
10  -2 mm 
-  29.3 ±  3,0  -- 
+  19.0  ±  3.9  <0.02 
-  33.3 _  1.3  NS* 
+  14,5  ±  3.0  <0.002 
-  11.3  ±  2.1  <0.001 
(CA)F~ were immunized with  107 ABA/A]J  and  107 ABA-BALB/c spleen cells  that  had  been subjected  to  1,500  rad 
gamma radiation.  In some groups, A/J spleen cells were treated  with monoclonal  anti-I A k (10.2.16)  and complement 
before ABA coupling. Mice were challenged in the footpad with 30 bd  10 raM-activated ABA solution 5 d after priming. 
DTH was measured 24 h  later. P  values were determined  by Student's t test. 
* Not significant. 
measure suppression. However, we have recently shown that F1 mice immunized with 
P1 ABA-coupled spleen cells are suppressed by P1 but not P2 TsFz (7). Exploiting this, 
we simultaneously immunized CAF1 mice with both anti-I-A  k +  G'-treated A/J ABA- 
coupled spleen ceils and normal BALB/c ABA-coupled spleen cells (Table II). In this 
way the BALB/c-ABA cells prime for CTL and DTH responses in the CAFx mouse, 
while the A/J-ABA cells prime the pre-Ts3, which can then be fully activated only by 
A/J TsF2 (7). As shown in Table II, A/J TsF2 can suppress CAF1 mice primed with 
anti-I-A  k +  C'-treated A/J ABA-coupled cells and BALB/c ABA-coupled cells, but 
not mice primed with BALB/c ABA-coupled cells alone. The effectiveness of the anti- 
I-A  k +  G' treatment  is shown by the inability of treated cells themselves to prime 
CAF1  mice  (Table III).  Thus  the  critical A/J  cell needed to  effect suppression  in 
concert with A/J TsF2 may be I-A  k negative. Although distinct from the I-A  + APC in 
its expression of class II antigens, the I-J  + APC is similar in its resistance to 1500 rad 
of x radiation (10)  (Table III). 
Because of the well-established cyclophosphamide sensitivity of the suppressor cell 
pathway (11), we investigated whether mice pretreated with low doses of cyclophos- 
phamide were deficient in this  I-J  + APC. We found that  normal  mice immunized 
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TABLE IV 
Cyclophosphamide Prelrealed  Mzce are Deficient zn Antagen Presenlation  for Suppression 
A. Delayed  Type H)persensitivz O, 
Immunization  TsFe  Footpad swelling  Percent sup-  P  value 
•  pression 
I0 -e mm 
ABA spleen ceils  -  22.0 _+  1.7  --  - 
Negative control  -  3.6 +  1.5  100  <  0.001 
ABA spleen cells  +  13.1  +  2.2  48  <  0.01 
Cy* pretreated  ABA spleen cells  -  21.2 -4=- 3.7  5  NS:~ 
Cy pretreated  ABA spleen cells  +  22,6 ±  23.9  0  NS 
B. Cytotoxicity 
Percent specific release of ABA 
Immunization  "['sFe  target 
100:1  33:1  11:1 
ABA spleen cells  -  87.1  61.9  27.1 
Negative control  -  15.8  9.7  6.5 
ABA spleen cells  +  1.2  4,7  5.7 
Cy-pretreated  ABA spleen cells  -  97.1  66.0  41.7 
Cy-pretreated  ABA spleen cells  +  89.3  68.0  46.7 
(CA)Ft  mice were  immunized  with  either  ABA-coupled  normal  (CA)FI spleen  cells  or ABA-coupled 
spleen cells from (CA)F~ mice pretreated  with 20 mg/kg cyclophnsphamide  2 d  befi~re  being killed. The 
data  in  Table  IVA  were  normalized  and  pooled  from  two  independent  experiments;  each  group 
contained  a  total of eight animals. Significance was determined  using the Student's  t test. 
* Cyclophosphamide. 
:~ Not significant. 
(20  mg/kg on  day  2)  were  primed  for normal  CTL  and  DTH  responses  to  ABA 
(Table IV). Thus the cell involved in the presentation of antigen for activation of Tsa 
appears to be sensitive to cyclophosphamide. This deficiency of I-J APC function in 
cyclophosphamide-pretreated animals might  also  be explained  by a  cyclophospha- 
mide-sensitive event required  for expression of I-J determinants.  Finally, the presen- 
tation  of antigen  in  a  manner  that  is  resistant  to  suppression  is  similar  to  the 
phenomenon reported by Britz et al.  (12). 
The data presented here supports the work of Nakamura et al. (13) who found that 
an  I-J  +  I-A- adherent  cell  was  required  for in  vitro induction  of Ts effector cells. 
There is also evidence that a special set of APC is required to trigger mixed leukocyte 
response suppressor activity (Susan  Rich, personal  communication).  Further,  it ap- 
pears likely that I-J-restricted events in other Ts pathways (4,  14) may be due to I-J- 
associated antigen  presentation.  Elimination  of the I-J  + APC may explain  why free 
antigen, usually not immunogenic when injected  intravenously, can immunize mice 
pretreated with cyclophosphamide (15).  Collectively, these experiments indicate that 
antigen can be processed by two distinct  APC  for activation of either suppressor or 
immune cells.  Selective manipulation of these APC subsets may permit modulation 
of immunity in a number of pathological processes (16-18). 
Summary 
We have found that an I-J  + I-A  antigen-presenting cell (APC)  is required for Tsa 
activation  in  vivo.  Together  with  the  I-J  restriction  previously  reported  for  Tsa 
induction  (Takaoki, M., M.-S. Sy, A. Tominaga, A. Lowy, M. Tsurifiji, B. Benacerraf, 
R. Finberg, and M. I. Greene,  1982,J.  Exp.  Med.,  156:1325),  it appears that this I-J  + 
APC is responsible for I-J restriction in the triggering of Tsa. This restriction may be LOWY  ET AL.  BRIEF DEFINITIVE REPORT  357 
exerted via a pre-Ts3 associative recognition of antigen and I-J encoded determinants, 
analogous  to  the  T  helper  recognition  of  antigen  in  the  context  of I-A  and  I-E 
determinants. 
The  authors  acknowledge the  expert  secretarial assistance of Ms.  Sarah  Curwood  and  the 
technical assistance of Ms. Jurate Dambrauskas. 
Received  for publication 12 October 1982. 
References 
1.  Sprent, J., R. Korngold, and K. Molnar-Kimber. 1980. T cell recognition of antigen in vivo: 
role of the H-2 complex. Springer Sere. Immunopathol. 3:215. 
2.  Schwartz, R. H., A. Yano, J. H. Stimpfling, and W. E. Paul. 1979. Gene complementation 
in the T-lymphocyte proliferative response to poly(Glu  55 Ly  s Pheg)n. A demonstration that 
both immune response gene products must be expressed in the same antigen-presenting 
cell.]. Exp. Med. 149:40. 
3.  Cullen, S. E., J. H. Freed, and S. G. Nathenson.  1976. Structural and serological properties 
of murine IA alloantigens. Transplant. Rev. 30:236. 
4.  Germain, R. N., and B.  Benacerraf.  1980.  T  helper and suppressor factors. Springer Sere. 
Immunopathol. 3:93. 
5.  Sy, M.-S., M. M. Dietz, R. N. Germain, B. Benacerraf, and M. I. Greene.  1980. Antigen 
and receptor-driven regulatory mechanisms.  IV. Idiotype-bearing I-J  + suppressor T  cell 
factors induce second-order suppressor cells which express anti-idiotype receptors. J. Exp. 
Med. 151:1183. 
6.  Tada, T. 1982. I region determinants expressed on different subsets ofT cells: their roles in 
immune  circuits.  In  Immunogenetics  and  Immune  Regulation.  B.  Benacerraf,  editor. 
Masson Italia Editore, Milan. 83-108. 
7.  Takaoki, M., M-S. Sy, A. Tominaga, A. Lowy, M. Tsurifiji, B. Benacerraf, R. Finberg, and 
M.  I. Greene.  1982. I-J-restricted interactions in the  generation of azobenzenearsonate- 
specific suppressor T  cells.`]. Exp. Med. 156:1325. 
8.  Bach, B. A., L. Sherman, B. Benacerraf, and M. I. Greene. 1978. Mechanisms of regulation 
of cell-mediated immunity. II. Induction and suppression of delayed-type hypersensitivity 
to azobenzenearsonate-coupled syngeneic cells.  J. Immunol. 121:1460. 
9.  Sherman,  L.,  S.  J.  Burakoff,  and  B.  Benacerraf.  1978.  The  induction  of cytolytic T 
lymphocytes with specificity of p-azophenylarsonate-coupled syngeneic cells. J.  lmmunoL 
121:1432. 
10.  Unanue,  E.  R.  1982. The  regulatory role of macrophages  in  antigenic stimulators.  II. 
Symbiotic relationship between lymphocytes and macrophages. Adv. Immunol. 33:1. 
11.  Gill, H. K., and F. Y. Liew. 1978. Regulation of delayed-type hypersensitivity. III. Effects 
of cyclophosphamide on  the suppressor cells for  delayed-type hypersensitivity to sheep 
erythrocytes in mice. Eur. J. lmmunol. 8:172. 
12.  Britz, J.  S.,  P.  W.  Askenase, W.  Ptak,  R.  M.  Steinman,  and  R.  K.  Gershon.  1982. 
Specialized antigen-presenting cells. Splenic dendritic and peritoneal-exudate cells induced 
by mycobacteria activate effector T  cells that  are resistant to suppression. J.  Exp.  Med. 
155:1344. 
13.  Nakamura, R. M., H. Tanaka, and T. Takunaga.  1982. In vitro induction of suppressor T- 
cells in delayed type hypersensitivity to BCG and an essential role of I-J positive accessory 
cells. ImmunoL Lett. 4:295. 
14.  Zembala, M., G. L. Asherson, and V. Colizzi. 1982. Hapten-specific T  suppressor factor 
recognizes  hapten  and  I-J  region  products  on  haptenated  spleen  cells. Nature (Lond.). 
297:411. 358  LOWY ET AL.  BRIEF DEFINITIVE  REPORT 
15.  Sy, M-S., A. R. Brown, B. Benacerraf, and M. I. Greene. 1980. Antigen and receptor-driven 
regulator mechanisms. III. Induction of delayed-type hypersensitivity to azobenzenearso- 
nate with anti-cross-reactive idiotype antibodies.J. Exp.  Med.  151:896. 
16.  Rolink, A. G., T. Radaszkiewicz, S. T. Pals, W. G. J.  van der Meer, and E. Gleichman. 
1982. Allosuppressor and allohelper T  cells in acute and chronic graft versus host disease. 
I. Alloreactive suppressor ceils rather than killer T  cells appear to be the decisive effector 
cells in lethal graft versus host disease.J. Exp.  Med.  155:1501. 
17.  Ben-Nun, A., and I.  R.  Cohen.  1982. Spontaneous remission and acquired resistance to 
auto-immune  encephalomyelitis (EAE) are associated with suppression of T cell reactivity. 
Suppressed EAE effector cells recovered as T cell lines. J. lmmunol.  128:1450. 
18.  Greene, M. I., S. Fujimoto, and A. M. Sehon. 1977. Regulation of the immune response to 
tumor antigens. III. Characterization of thymus suppressor factor(s)  produced by tumor- 
bearing hosts. J. Immunol. 119:757. 